Literature DB >> 8173542

'Cognitive inhibition' and positive symptomatology in schizotypy.

E R Peters1, A D Pickering, D R Hemsley.   

Abstract

The negative priming paradigm (Tipper, 1985) was used to investigate the relationship between 'cognitive inhibition' and symptoms of reality distortion in schizotypy, after previous findings that the negative priming effect is reduced in both acute schizophrenics and high schizotypes (Beech, Powell, McWilliam & Claridge, 1989; Beech, Baylis, Smithson & Claridge, 1989). Following Frith's (1979) model, which suggests that the positive symptoms of schizophrenia are due to a failure of the inhibitory processes which normally limit the contents of consciousness, it was predicted that negative priming would be inversely correlated with levels of positive symptomatology, as measured by the CSTQ (Bentall, Claridge & Slade, 1989). The results supported the hypothesis, which confirms the usefulness of a symptom-oriented approach as well as providing some validation for the concept of schizotypy. It was concluded that high schizotypes, similarly to acute schizophrenics, show a reduction in 'cognitive inhibition', as was predicted by Frith's (1979) model.

Entities:  

Mesh:

Year:  1994        PMID: 8173542     DOI: 10.1111/j.2044-8260.1994.tb01092.x

Source DB:  PubMed          Journal:  Br J Clin Psychol        ISSN: 0144-6657


  10 in total

1.  Attentional window in schizophrenia and schizotypal personality: Insight from negative priming studies.

Authors:  Randall K Minas; Sohee Park
Journal:  Appl Prev Psychol       Date:  2007-12

Review 2.  Cognition and brain function in schizotypy: a selective review.

Authors:  Ulrich Ettinger; Christine Mohr; Diane C Gooding; Alex S Cohen; Alexander Rapp; Corinna Haenschel; Sohee Park
Journal:  Schizophr Bull       Date:  2015-03       Impact factor: 9.306

3.  Association of Schizotypy With Dimensions of Cognitive Control: A Meta-Analysis.

Authors:  Maria Steffens; Inga Meyhöfer; Kaja Fassbender; Ulrich Ettinger; Joseph Kambeitz
Journal:  Schizophr Bull       Date:  2018-10-15       Impact factor: 9.306

4.  Relation between cognitive dysfunction and pseudobulbar palsy in amyotrophic lateral sclerosis.

Authors:  S Abrahams; L H Goldstein; A Al-Chalabi; A Pickering; R G Morris; R E Passingham; D J Brooks; P N Leigh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-05       Impact factor: 10.154

5.  Individual differences in the executive control of attention, memory, and thought, and their associations with schizotypy.

Authors:  Michael J Kane; Matt E Meier; Bridget A Smeekens; Georgina M Gross; Charlotte A Chun; Paul J Silvia; Thomas R Kwapil
Journal:  J Exp Psychol Gen       Date:  2016-06-16

6.  Examining the Psychosis Continuum.

Authors:  Pamela DeRosse; Katherine H Karlsgodt
Journal:  Curr Behav Neurosci Rep       Date:  2015-05-01

Review 7.  Are Hallucinations Due to an Imbalance Between Excitatory and Inhibitory Influences on the Brain?

Authors:  Renaud Jardri; Kenneth Hugdahl; Matthew Hughes; Jérôme Brunelin; Flavie Waters; Ben Alderson-Day; Dave Smailes; Philipp Sterzer; Philip R Corlett; Pantelis Leptourgos; Martin Debbané; Arnaud Cachia; Sophie Denève
Journal:  Schizophr Bull       Date:  2016-06-03       Impact factor: 9.306

8.  Altered patterns of cortical activation in ALS patients during attention and cognitive response inhibition tasks.

Authors:  L H Goldstein; I C Newsom-Davis; V Bryant; M Brammer; P N Leigh; A Simmons
Journal:  J Neurol       Date:  2011-05-10       Impact factor: 4.849

9.  Cognitive predictors of longitudinal positive symptom course in clinical high risk for psychosis.

Authors:  Ingvild Aase; Johannes Hendrik Langeveld; Jan Olav Johannessen; Inge Joa; Ingvild Dalen; Wenche Ten Velden Hegelstad
Journal:  Schizophr Res Cogn       Date:  2021-07-28

10.  Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies.

Authors:  I Koychev; D Joyce; E Barkus; U Ettinger; A Schmechtig; C T Dourish; G R Dawson; K J Craig; J F W Deakin
Journal:  Transl Psychiatry       Date:  2016-05-17       Impact factor: 6.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.